Vericel (FRA:ATQP) Insider Ownership : 0.00 % (As of May. 11, 2025)

View and export this data going back to 2007. Start your Free Trial

What is Vericel Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Vericel's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Vericel's Institutional Ownership is 81.30%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Vericel's Float Percentage Of Total Shares Outstanding is 76.68%.

Vericel Insider Ownership Historical Data

The historical data trend for Vericel's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vericel Insider Ownership Chart

Vericel Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Insider Ownership

Get a 7-Day Free Trial

Vericel Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Insider Ownership	Get a 7-Day Free Trial															-	-	-	-	-

Vericel Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Vericel Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vericel Corp (FRA:ATQP) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

VCEL:USA ATQP:Germany

Address

64 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.vcel.com

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Vericel Headlines

No Headlines